FDA Pipeline Preview, May 2011 (Eli Lilly, Vertex, Regeneron Pharmaceuticals, Nile Therapeutics, Provectus)

May 1, 2011

Recent FDA action (through April 2011) related to Liprotamase, Aricept Patch, Telaprevir, Restylane Injectable Gel, VEGF Trap-Eye, Cenderitide, PV-10, INNO-206

Complete response

Recommended for approval

Priority review

Orphan drug designation